Roche Discussing Phase III Study with FDA for Personalized Asthma Drug Lebrikizumab | GenomeWeb

By Turna Ray

Roche subsidiary Genentech is planning a Phase III study to confirm early-stage findings suggesting that its investigational drug lebrikizumab will be efficacious for a molecularly defined subpopulation of asthma patients whose symptoms aren't managed properly with standard treatments.

"Lebrikizumab is a potential new therapeutic for asthma that is inadequately controlled despite inhaled corticosteroids and long-acting beta 2 agonists," a company spokesperson told PGx Reporter this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Through a transcriptome study, researchers home in on the activity of inflammation-linked genes in chronically lonely people.

Determining who is and is not an author and where a researcher should fall on a list of authors can be a tricky task, Nature News writes.

In PNAS this week: variant protective against Alzheimer's disease, effect of whole-genome duplication on methylation in rice, and more.

Genome editing is also bringing up questions when applied to farm animals, the New York Times reports.